Table: Peptidream -9-MTH group results (IFRS)
Nov 13 (Reuters)-
Peptidream Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2024 Sep 30, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 41.60 22.54 45.00
(+84.5 pct) (+101.1 pct) (+56.7 pct)
Operating 24.52 6.75 20.10
(+263.1 pct) (+196.8 pct)
Pretax 24.30 4.66 19.90
(+421.3 pct) (+357.1 pct)
Net 17.62 3.54 14.00
(+397.6 pct) (+361.2 pct)
EPS Basic 135.95 yen 27.30 yen
EPS Diluted 135.76 yen 27.27 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Peptidream Inc..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4587.T
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner